Canada

A new, international group of health technology assessment agencies will work together on topics related to health economic methods that could include dynamic pricing and non-traditional ways of evaluating value in cost-effectiveness analyses.

As mandated by the recent Pharmacare Act in Canada, a new committee will make recommendations on how Canada can provide universal drug coverage to it citizens.

Canada’s shortage of children’s analgesic/antipyretic OTCs in 2022 as COVID-19 and seasonal flu virus combined to drive stockpiling by consumers. Some poison control centers and hospitals offered recommendations about modifying adult doses to pediatric use.

The latest campaign from Biosimilars Canada, #SaveBigWithBiosimilars, targets businesses to raise awareness of the benefits of using biosimilars for employee health benefit plans.

The roadmap sets out eight steps to help registry teams link data from registry records with administrative health services data.

Darrin Schellin leads Pharma Tech; PLT expands leadership with Weiss as brand mmanagement head; Tuttle joins ProPharma as CFO; Burgher leads Arbonne marketing, growth; Evvy appoints first medical chief; Vitaquest appoints David Alcaraz quality assurance head; and Lemon Water leadership in transition from founder.

Generics Bulletin reviews the latest regulatory developments across the world.

Firm’s future, as a separate business nearly 90% owned by Bausch Health, or as a standalone with different ownership or one not controlled by a majority owner, claims high profile in analysts’ comments and predictions. B+L is in the driver’s seat, they say.

Beachbody offers supplement sales using health savings accounts; PlantX, Boka launches oral health supplements; supplements take Form from RTE meal provider Factor; LIV3 JV behind marketing SugarShield; Ghost among Keurig Dr Pepper brands; and Nutra-Med Packaging expands with Legacy Pharma.

After sharing multiple updates to the regulatory status of its ketamine formulation, PharmaTher received a complete response letter from the FDA, which required minor information and clarifications from the company.